Jul. 7 at 3:29 PM
$SNDX forecast
$87.8MM in FY25 Niktimvo sales @ 12/31/24 as SNDX recorded a
$12.116 current liability at 12/31/24 to accrue the estimated 13.8% royalty due
$RPRX. FY25 is Niktimvo's 1st full year on the market
When
$KDMN was acquired for
$1.9B by Sanofi in 9/21, KDMN forecast
$63MM in Rezurock sales for its 1st full year on the market (per attachment). Using these estimates, Niktimvo is forecast to generate ~40% more dollars in 1st full year sales (both were approved mid-summer the prior year)
Niktimvo's clinical profile appears almost identical to Rezurock per attached FDA press releases. Niktimvo has a slight advantage with a faster time to 1st response
If new drugs are worth a multiple of projected sales, & if Niktimvo is forecast to generate ~40% more sales dollars in 1st year sales, does this mean Niktimvo's hypothetical M&A value is ~40% more than Rezurock? This is a question & not a statement.
SNDX splits Niktimvo profits/losses 50/50 with
$INCY but sold a 13.8% royalty to RPRX
